OTULIN-Related Autoinflammatory Syndrome (ORAS)
OTULIN-related autoinflammatory syndrome (ORAS), also called otulipenia, is a rare and serious inherited autoinflammatory disease caused by loss-of-function mutations in the OTULIN gene. This gene encodes an enzyme that regulates the assembly of ubiquitin chains, an important brake that keeps inflammatory responses inside cells in check. Without enough OTULIN, the NF-κB signaling pathway stays switched on, producing a cytokine storm that damages the skin, joints and blood vessels.
At Haute-Derma, we treat ORAS as a condition that calls for active medical treatment from the earliest stage. Drawing on an understanding of its complex molecular mechanism, we use advanced biologic therapies to restore immune balance, heal severe skin lesions and protect the patient's overall development.
Our Approach to Treating ORAS
Our specialists at Haute-Derma focus on directly blocking the inflammatory cytokines unleashed by uncontrolled NF-κB activity. We know that patients with ORAS often face prolonged high fevers and severe pustular skin inflammation from the first weeks of life.
We lead in using therapies targeted at TNF-alpha, the main driver of inflammation in this syndrome. At Haute-Derma, every treatment plan is built through collaboration between dermatology, immunology and genetics to achieve the best and most durable results.
Our ORAS care pathway includes:
- OTULIN gene sequencing to identify the exact mutation.
- Anti-TNF-alpha biologic therapy to bring systemic inflammation under control quickly.
- Specialized skin and soft tissue care to prevent scarring and skin necrosis.
How We Diagnose ORAS at Haute-Derma
Because ORAS is easily mistaken for neonatal sepsis or other autoinflammatory syndromes, Haute-Derma follows a rigorous diagnostic process:
- Assessing signs in early infancy: Recurrent high fevers, painful red nodular rashes (erythema nodosum–like) and swollen joints.
- Looking for subcutaneous fat involvement: Checking for synovitis and inflammation of the fat layer (panniculitis), a very characteristic feature of ORAS.
- Acute inflammatory markers: Monitoring CRP, erythrocyte sedimentation rate and blood cytokines (particularly TNF), which rise well above normal.
- Skin and tissue biopsy: Looking for neutrophilic infiltrates and fat cell necrosis driven by unchecked NF-κB activation.
- Molecular genetic testing: Identifying recessive OTULIN mutations to confirm the diagnosis.
How Is ORAS Treated at Haute-Derma?
Our treatment aims to stop inflammatory signaling at its source:
- Anti-TNF-alpha therapy (infliximab/adalimumab): This is the gold standard for ORAS at Haute-Derma. These drugs neutralize excess TNF-alpha, clear inflammatory skin nodules and stop fevers quickly, often with dramatic results.
- Interleukin-1 (IL-1) inhibitors: Considered as add-on treatment for complex systemic inflammation or a poor response to anti-TNF therapy alone.
- Nutrition and growth support: Chronic inflammation burns a great deal of energy, so we provide tailored nutritional support to help children with ORAS catch up on growth.
- Preventing vascular complications: Close monitoring for vasculitis to prevent thrombosis or silent organ damage.
- Genetic counseling for families: Helping parents understand recessive inheritance and offering screening options for future pregnancies.
